Inventor · disambiguated record
Ray Camphausen
Also filed as: CAMPHAUSEN RAY
47 granted patents·11 pending applications·1,016 citations·filing 1995–2023
99Inventor score
Top patents by PatentIndex Score
58 records- 0197US9434778B2Modified FGF-21 polypeptides comprising an internal deletion and uses thereofBRISTOL MYERS SQUIBB CO·Filed 2015·Granted Sep 6, 2016·31 cites·20 claims
- 0297US8420098B2Fibronectin based scaffold domain proteins that bind to PCSK9CAMPHAUSEN RAY·Filed 2011·Granted Apr 16, 2013·86 cites·8 claims
- 0396US9920108B2Targeted therapeutics based on engineered proteins that bind EGFRBRISTOL MYERS SQUIBB CO·Filed 2015·Granted Mar 20, 2018·19 cites·14 claims
- 0496US9771411B2Method of treating cancer by administering EGFR and EGFR/IGFIR binding moleculesBRISTOL MYERS SQUIBB CO·Filed 2015·Granted Sep 26, 2017·22 cites·20 claims
- 0596US9522951B2Fibronectin binding domains with reduced immunogenicityBRISTOL MYERS SQUIBB CO·Filed 2012·Granted Dec 20, 2016·18 cites·20 claims
- 0696US9416170B2Fibronectin binding domains with reduced immunogenicityBRISTOL MYERS SQUIBB CO·Filed 2013·Granted Aug 16, 2016·16 cites·45 claims
- 0796US9017655B2Bispecific EGFR/IGFIR binding moleculesBRISTOL MYERS SQUIBB CO·Filed 2012·Granted Apr 28, 2015·36 cites·10 claims
- 0896US8524244B2Targeted therapeutics based on engineered proteins that bind EGFRCAMPHAUSEN RAY·Filed 2009·Granted Sep 3, 2013·44 cites·24 claims
- 0996US8470332B2Targeted therapeutics based on engineered proteins for tyrosine kinases receptors, including IGF-IRCAMPHAUSEN RAY·Filed 2007·Granted Jun 25, 2013·41 cites·13 claims
- 1096US8343501B2Bispecific EGFR/IGFIR binding moleculesBRISTOL MYERS SQUIBB CO·Filed 2009·Granted Jan 1, 2013·45 cites·19 claims
- 1196US8221765B2Multivalent fibronectin based scaffold domain proteinsCAMPHAUSEN RAY·Filed 2009·Granted Jul 17, 2012·66 cites·20 claims
- 1295US9902762B2Multivalent fibronectin based scaffold domain proteinsBRISTOL MYERS SQUIBB CO·Filed 2014·Granted Feb 27, 2018·28 cites·10 claims
- 1395US9234028B2Targeted therapeutics based on engineered proteins that bind EGFRBRISTOL MYERS SQUIBB CO·Filed 2013·Granted Jan 12, 2016·30 cites·19 claims
- 1495US8728483B2Multivalent fibronectin based scaffold domain proteinsCAMPHAUSEN RAY·Filed 2012·Granted May 20, 2014·38 cites·29 claims
- 1595US5827817AP-selectin ligand proteinGENETICS INST·Filed 1995·Granted Oct 27, 1998·146 cites·16 claims
- 1694US10189883B2Therapeutic uses of modified FGF-21 polypeptidesBRISTOL MYERS SQUIBB CO·Filed 2017·Granted Jan 29, 2019·12 cites·20 claims
- 1794US9631004B2Modified FGF-21 polypeptides comprising an internal deletion and uses thereofBRISTOL MYERS SQUIBB CO·Filed 2016·Granted Apr 25, 2017·12 cites·17 claims
- 1894US9540424B2Serum albumin binding moleculesBRISTOL MYERS SQUIBB CO·Filed 2014·Granted Jan 10, 2017·27 cites·19 claims
- 1994US9469676B2Fc fusion proteins comprising novel linkers or arrangementsCAMPHAUSEN RAY·Filed 2012·Granted Oct 18, 2016·19 cites·7 claims
- 2094US8969289B2Serum albumin binding moleculesGOSSELIN MICHAEL L·Filed 2011·Granted Mar 3, 2015·45 cites·33 claims
- 2193US10604556B2Fibronectin binding domains with reduced immunogenicityBRISTOL MYERS SQUIBB CO·Filed 2016·Granted Mar 31, 2020·5 cites·20 claims
- 2293US10221438B2Serum albumin binding moleculesBRISTOL MYERS SQUIBB CO·Filed 2016·Granted Mar 5, 2019·12 cites·16 claims
- 2393US9765132B2Fibronectin binding domains with reduced immunogenicityBRISTOL MYERS SQUIBB CO·Filed 2013·Granted Sep 19, 2017·9 cites·46 claims
- 2492US10774130B2Method of treating cancer by administering multivalent fibronectin based scaffold domain proteinsBRISTOL MYERS SQUIBB CO·Filed 2018·Granted Sep 15, 2020·6 cites·15 claims
- 2592US9856309B2Fibronectin based scaffold domain proteins that bind PCSK9BRISTOL MYERS SQUIBB CO·Filed 2015·Granted Jan 2, 2018·10 cites·16 claims
- 2692US9562089B2Fibronectin based scaffold proteins having improved stabilityCAMPHAUSEN RAY·Filed 2011·Granted Feb 7, 2017·24 cites·14 claims
- 2792US5840679AMethod of inhibiting P-selectin ligand activityGENETICS INST·Filed 1995·Granted Nov 24, 1998·98 cites·26 claims
- 2891US10947297B2Fibronectin based scaffold domain proteins that bind PCSK9BRISTOL MYERS SQUIBB CO·Filed 2017·Granted Mar 16, 2021·5 cites·19 claims
- 2991US10934572B2Serum albumin binding moleculesBRISTOL MYERS SQUIBB CO·Filed 2019·Granted Mar 2, 2021·4 cites·16 claims
- 3091US10183987B2Polynucleotides encoding bispecific EGFR/IGF-IR binding moleculesBRISTOL MYERS SQUIBB CO·Filed 2017·Granted Jan 22, 2019·7 cites·13 claims
- 3190US10954286B2Bispecific EGFR/IGFIR binding moleculesBRISTOL MYERS SQUIBB CO·Filed 2018·Granted Mar 23, 2021·2 cites·20 claims
- 3290US10442851B2Serum albumin-binding fibronectin type III domainsBRISTOL MYERS SQUIBB CO·Filed 2015·Granted Oct 15, 2019·5 cites·12 claims
- 3390US10377806B2Methods of treating diseases associated with fibrosis using modified FGF-21 polypeptides and uses thereofBRISTOL MYERS SQUIBB CO·Filed 2018·Granted Aug 13, 2019·6 cites·30 claims
- 3490US10221232B2Methods of treating cancer by administering IGF-IR binding moleculesBRISTOL MYERS SQUIBB CO·Filed 2017·Granted Mar 5, 2019·7 cites·10 claims
- 3590US9234027B2Fibronectin based scaffold domain proteins that bind PCSK9BRISTOL MYERS SQUIBB CO·Filed 2013·Granted Jan 12, 2016·10 cites·22 claims
- 3689US10781247B2Targeted therapeutics based on engineered proteins that bind EGFRBRISTOL MYERS SQUIBB CO·Filed 2018·Granted Sep 22, 2020·3 cites·17 claims
- 3788US11248031B2Methods of treating diseases associated with fibrosis using modified FGF-21 polypeptidesBRISTOL MYERS SQUIBB CO·Filed 2019·Granted Feb 15, 2022·4 cites·22 claims
- 3888US10273286B2Fibronectin based scaffold proteins having improved stabilityBRISTOL MYERS SQUIBB CO·Filed 2016·Granted Apr 30, 2019·7 cites·8 claims
- 3988US10214579B2Fc fusion proteins comprising novel linkers or arrangementsBRISTOL MYERS SQUIBB CO·Filed 2016·Granted Feb 26, 2019·3 cites·9 claims
- 4087US10464995B2Fibronectin binding domains with reduced immunogenicityBRISTOL MYERS SQUIBB CO·Filed 2016·Granted Nov 5, 2019·2 cites·17 claims
- 4186US11203630B2Serum albumin-binding fibronectin type III domainsBRISTOL MYERS SQUIBB CO·Filed 2019·Granted Dec 21, 2021·2 cites·9 claims
- 4286US11161893B2Fibronectin based scaffold proteins having improved stabilityBRISTOL MYERS SQUIBB CO·Filed 2019·Granted Nov 2, 2021·2 cites·10 claims
- 4386US2024239870A1Fibronectin based scaffold domain proteins that bind pcsk9BRISTOL MYERS SQUIBB CO·Filed 2023·Application pending·0 cites
- 4485US11408093B2Fibronectin binding domains with reduced immunogenicityBRISTOL MYERS SQUIBB CO·Filed 2020·Granted Aug 9, 2022·1 cites·20 claims
- 4584US2023183885A1Fibronectin binding domains with reduced immunogenicityBRISTOL MYERS SQUIBB CO·Filed 2022·Application pending·0 cites
- 4682US11149077B2Targeted therapeutics based on engineered proteins for tyrosine kinases receptors, including IGF-IRBRISTOL MYERS SQUIBB CO·Filed 2019·Granted Oct 19, 2021·1 cites·10 claims
- 4782US2022275535A1Fibronectin binding domains with reduced immunogenicityBRISTOL MYERS SQUIBB CO·Filed 2022·Application pending·0 cites
- 4880US12247058B2Nucleic acids encoding modified FGF-21 polypeptides, vectors and cells containing, and use thereofBRISTOL MYERS SQUIBB CO·Filed 2021·Granted Mar 11, 2025·0 cites·21 claims
- 4978US11279751B2Fibronectin binding domains with reduced immunogenicityBRISTOL MYERS SQUIBB CO·Filed 2019·Granted Mar 22, 2022·0 cites·20 claims
- 5076US11858979B2Fibronectin based scaffold domain proteins that bind PCSK9BRISTOL MYERS SQUIBB CO·Filed 2021·Granted Jan 2, 2024·0 cites·10 claims
Showing the top 50 of 58 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when Ray Camphausen files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →